Clinical Trial Update: Risankizumab Long-term Remission Study [Phase 4]

View source ↗

Summary

Update on the Phase 4 Risankizumab long-term remission study shows the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: Jaehwan Kim | Conditions: Psoriasis | Phase 4 | Status: ACTIVE_NOT_RECRUITING